Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-doze zidovudine and lamivudine, as initial therapy for patients infected with HIV
Article Abstract:
The antiviral efficacy and the safety of once-daily atazanavir 400 mg, an azapeptide protease inhibitor (PI), is compared with efavirenz 600 mg, each in combination with open-label fixed-dose zidovudine plus lamivudine twice daily. The results suggest that for initial HIV treatment, a highly active antiretroviral therapy regimen of atazanavir/zidovudine/lamivudine is as effective and well tolerated as the combination of efavirenz/zidovudine/lamivudine.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Novel therapies based on mechanisms of HIV-1 cell entry
Article Abstract:
Novel classes of safe and effective agents with a low risk of cross-resistance with other antiretroviral drugs are required to reduce the incidence of the human immunodeficiency virus type 1 (HIV-1). The steps involved in viral attachment and entry are outlined and the prospects of the compounds in the treatment of HIV infection are considered.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
- Abstracts: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen into 1 and 2 clinical trials